The Texas Medication Algorithm Project

Clinical results for schizophrenia

Alexander L. Miller, M. Lynn Crismon, A. John Rush, John Chiles, T. Michael Kashner, Marcia Toprac, Thomas Carmody, Melanie Biggs, Kathy Shores-Wilson, Judith Chiles, Brad Witte, Christine Bow-Thomas, Dawn I. Velligan, Madhukar Trivedi, Trisha Suppes, Steven Shon

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

In the Texas Medication Algorithm Project (TMAP), patients were given algorithm-guided treatment (ALGO) or treatment as usual (TAU). The ALGO intervention included a clinical coordinator to assist the physicians and administer a patient and family education program. The primary comparison in the schizophrenia module of TMAP was between patients seen in clinics in which ALGO was used (n = 165) and patients seen in clinics in which no algorithms were used (M = 144). A third group of patients, seen in clinics using an algorithm for bipolar or major depressive disorder but not for schizophrenia, was also studied (M = 156). The ALGO group had modestly greater improvement in symptoms (Brief Psychiatric Rating Scale) during the first quarter of treatment. The TAU group caught up by the end of 12 months. Cognitive functions were more improved in ALGO than in TAU at 3 months, and this difference was greater at 9 months (the final cognitive assessment). In secondary comparisons of ALGO with the second TAU group, the greater improvement in cognitive functioning was again noted, but the initial symptom difference was not significant.

Original languageEnglish (US)
Pages (from-to)627-647
Number of pages21
JournalSchizophrenia Bulletin
Volume30
Issue number3
StatePublished - 2004

Fingerprint

Schizophrenia
Therapeutics
Brief Psychiatric Rating Scale
Major Depressive Disorder
Patient Education
Cognition
Physicians

Keywords

  • Algorithm
  • Guideline
  • Medication
  • Schizophrenia
  • Symptoms

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Miller, A. L., Crismon, M. L., Rush, A. J., Chiles, J., Kashner, T. M., Toprac, M., ... Shon, S. (2004). The Texas Medication Algorithm Project: Clinical results for schizophrenia. Schizophrenia Bulletin, 30(3), 627-647.

The Texas Medication Algorithm Project : Clinical results for schizophrenia. / Miller, Alexander L.; Crismon, M. Lynn; Rush, A. John; Chiles, John; Kashner, T. Michael; Toprac, Marcia; Carmody, Thomas; Biggs, Melanie; Shores-Wilson, Kathy; Chiles, Judith; Witte, Brad; Bow-Thomas, Christine; Velligan, Dawn I.; Trivedi, Madhukar; Suppes, Trisha; Shon, Steven.

In: Schizophrenia Bulletin, Vol. 30, No. 3, 2004, p. 627-647.

Research output: Contribution to journalArticle

Miller, AL, Crismon, ML, Rush, AJ, Chiles, J, Kashner, TM, Toprac, M, Carmody, T, Biggs, M, Shores-Wilson, K, Chiles, J, Witte, B, Bow-Thomas, C, Velligan, DI, Trivedi, M, Suppes, T & Shon, S 2004, 'The Texas Medication Algorithm Project: Clinical results for schizophrenia', Schizophrenia Bulletin, vol. 30, no. 3, pp. 627-647.
Miller AL, Crismon ML, Rush AJ, Chiles J, Kashner TM, Toprac M et al. The Texas Medication Algorithm Project: Clinical results for schizophrenia. Schizophrenia Bulletin. 2004;30(3):627-647.
Miller, Alexander L. ; Crismon, M. Lynn ; Rush, A. John ; Chiles, John ; Kashner, T. Michael ; Toprac, Marcia ; Carmody, Thomas ; Biggs, Melanie ; Shores-Wilson, Kathy ; Chiles, Judith ; Witte, Brad ; Bow-Thomas, Christine ; Velligan, Dawn I. ; Trivedi, Madhukar ; Suppes, Trisha ; Shon, Steven. / The Texas Medication Algorithm Project : Clinical results for schizophrenia. In: Schizophrenia Bulletin. 2004 ; Vol. 30, No. 3. pp. 627-647.
@article{353c513da63f4b809896915ba4cd5cb0,
title = "The Texas Medication Algorithm Project: Clinical results for schizophrenia",
abstract = "In the Texas Medication Algorithm Project (TMAP), patients were given algorithm-guided treatment (ALGO) or treatment as usual (TAU). The ALGO intervention included a clinical coordinator to assist the physicians and administer a patient and family education program. The primary comparison in the schizophrenia module of TMAP was between patients seen in clinics in which ALGO was used (n = 165) and patients seen in clinics in which no algorithms were used (M = 144). A third group of patients, seen in clinics using an algorithm for bipolar or major depressive disorder but not for schizophrenia, was also studied (M = 156). The ALGO group had modestly greater improvement in symptoms (Brief Psychiatric Rating Scale) during the first quarter of treatment. The TAU group caught up by the end of 12 months. Cognitive functions were more improved in ALGO than in TAU at 3 months, and this difference was greater at 9 months (the final cognitive assessment). In secondary comparisons of ALGO with the second TAU group, the greater improvement in cognitive functioning was again noted, but the initial symptom difference was not significant.",
keywords = "Algorithm, Guideline, Medication, Schizophrenia, Symptoms",
author = "Miller, {Alexander L.} and Crismon, {M. Lynn} and Rush, {A. John} and John Chiles and Kashner, {T. Michael} and Marcia Toprac and Thomas Carmody and Melanie Biggs and Kathy Shores-Wilson and Judith Chiles and Brad Witte and Christine Bow-Thomas and Velligan, {Dawn I.} and Madhukar Trivedi and Trisha Suppes and Steven Shon",
year = "2004",
language = "English (US)",
volume = "30",
pages = "627--647",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The Texas Medication Algorithm Project

T2 - Clinical results for schizophrenia

AU - Miller, Alexander L.

AU - Crismon, M. Lynn

AU - Rush, A. John

AU - Chiles, John

AU - Kashner, T. Michael

AU - Toprac, Marcia

AU - Carmody, Thomas

AU - Biggs, Melanie

AU - Shores-Wilson, Kathy

AU - Chiles, Judith

AU - Witte, Brad

AU - Bow-Thomas, Christine

AU - Velligan, Dawn I.

AU - Trivedi, Madhukar

AU - Suppes, Trisha

AU - Shon, Steven

PY - 2004

Y1 - 2004

N2 - In the Texas Medication Algorithm Project (TMAP), patients were given algorithm-guided treatment (ALGO) or treatment as usual (TAU). The ALGO intervention included a clinical coordinator to assist the physicians and administer a patient and family education program. The primary comparison in the schizophrenia module of TMAP was between patients seen in clinics in which ALGO was used (n = 165) and patients seen in clinics in which no algorithms were used (M = 144). A third group of patients, seen in clinics using an algorithm for bipolar or major depressive disorder but not for schizophrenia, was also studied (M = 156). The ALGO group had modestly greater improvement in symptoms (Brief Psychiatric Rating Scale) during the first quarter of treatment. The TAU group caught up by the end of 12 months. Cognitive functions were more improved in ALGO than in TAU at 3 months, and this difference was greater at 9 months (the final cognitive assessment). In secondary comparisons of ALGO with the second TAU group, the greater improvement in cognitive functioning was again noted, but the initial symptom difference was not significant.

AB - In the Texas Medication Algorithm Project (TMAP), patients were given algorithm-guided treatment (ALGO) or treatment as usual (TAU). The ALGO intervention included a clinical coordinator to assist the physicians and administer a patient and family education program. The primary comparison in the schizophrenia module of TMAP was between patients seen in clinics in which ALGO was used (n = 165) and patients seen in clinics in which no algorithms were used (M = 144). A third group of patients, seen in clinics using an algorithm for bipolar or major depressive disorder but not for schizophrenia, was also studied (M = 156). The ALGO group had modestly greater improvement in symptoms (Brief Psychiatric Rating Scale) during the first quarter of treatment. The TAU group caught up by the end of 12 months. Cognitive functions were more improved in ALGO than in TAU at 3 months, and this difference was greater at 9 months (the final cognitive assessment). In secondary comparisons of ALGO with the second TAU group, the greater improvement in cognitive functioning was again noted, but the initial symptom difference was not significant.

KW - Algorithm

KW - Guideline

KW - Medication

KW - Schizophrenia

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=10344222178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344222178&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 627

EP - 647

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 3

ER -